|Slideshows|May 24, 2021

10 Critical Conversations to Evaluate the Status Quo in Psychiatry

Noteworthy arguments that challenge the state of affairs in psychiatry.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Psychiatrists Already Practice Comprehensive, Holistic Care—but More Resources Are Needed

ByJohn J. Miller, MD

May 8th 2026

Why Global Integration Is Essential for the Future of DSM

ByJohn J. Miller, MD

February 5th 2026

Is the DSM Helping or Hindering Patient Care? Rethinking Diagnosis, FDA Approval, and Access to Treatment

ByJohn J. Miller, MD

January 29th 2026

A Psychiatrist's Reflections on the Country

ByFrank A. Clark, MD

September 11th 2025

Robert Jay Lifton, MD: Lifting Us Up From Our Human Abyss

ByH. Steven Moffic, MD

September 5th 2025

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

10 Critical Conversations to Evaluate the Status Quo in Psychiatry

Related Content

Psychiatrists Already Practice Comprehensive, Holistic Care—but More Resources Are Needed

Why Global Integration Is Essential for the Future of DSM

Is the DSM Helping or Hindering Patient Care? Rethinking Diagnosis, FDA Approval, and Access to Treatment

A Psychiatrist's Reflections on the Country

Robert Jay Lifton, MD: Lifting Us Up From Our Human Abyss

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

Why Cultural Context Matters in Psychiatric Assessment

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care